Travere Q4 FILSPARI sales $49.6M; plans FSGS sNDA by end Q1 2025

Travere Therapeutics, Inc.

2024-FY EPS reported -$4.08 revenue$233,175,000

Q4 total net product sales $73.5M (FILSPARI $49.6M); FY total $226.7M (FILSPARI $132.2M).
Plans to submit sNDA for FILSPARI in FSGS around end of Q1 2025, based on Phase 3 DUPLEX and Phase 2 DUET.
FDA granted full approval for IgAN in Sept 2024; received 693 new patient start forms in Q4.
Pegtibatinase Phase 3 HARMONY restart expected in 2026 after manufacturing scale-up improvements.
Cash and marketable securities $370.7M as of Dec 31, 2024, including $134.7M from Nov stock offering.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.